132 results on '"Mazzoni, Sandra"'
Search Results
2. Novel high–risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53
3. Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.
4. Comprehensive assessment of adverse event profiles associated with bispecific T cell engagers in multiple myeloma.
5. Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients
6. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.
7. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.
8. Role of Palliative Care in the Supportive Management of AL Amyloidosis—A Review
9. S3347 Successful Endoscopic Submucosal Dissection of a Gastroesophageal Junction Adenocarcinoma in a Patient with a Severe Bleeding Diathesis
10. P-256 Initial report of a single institution experience with teclistamab for relapsed or refractory multiple myeloma including prior BCMA
11. P-465 Global disparities in multiple myeloma: examining adverse events and drug toxicity trends
12. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma
13. Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice
14. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation
15. The Characteristics of Multiple Myeloma Patients Referred for CAR T-Cell Therapy
16. Incidence of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
17. Factors That Predict Early Relapse Post Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
18. Analysis of Factors That Predict Progression Free and Overall Survival Post Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
19. Safety and Efficacy of Continuous Use Avatrombopag in Chronic Liver Disease
20. Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
21. Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study
22. The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
23. Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma
24. Managing Kidney Disease in Patients with Sickle Cell Disease: A Quality Initiative at the Cleveland Clinic
25. Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma
26. Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma
27. External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs
28. Clinical utility of chromosomal microarray in establishing clonality and high risk features in patients with Richter transformation
29. Clinical Utility of Chromosomal Microarray in Establishing Clonality and High Risk Features in Patients with Richter Transformation
30. Tumor lysis syndrome in anti-androgen-treated metastatic prostate cancer
31. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study
32. P-375 Unraveling signaling pathways in multiple myeloma cardiovascular toxicities from pharmacovigilance and pharmacogenomics data mining
33. P-366 Signaling pathway data analytics of nephropathy and neuropathy from drug toxicities in multiple myeloma
34. P-127 Bone marrow plasmacytosis >5% at time of autologous transplant influences survival outcomes in patients with standard risk cytogenetics
35. Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase.
36. NS-62: The Importance of regular disease monitoring for patients with low or low intermediate risk Monoclonal Gammopathy of Undetermined Significance (MGUS)
37. Validation of the IMPEDE VTE Score for Prediction of Venous Thromboembolism in Multiple Myeloma: A Retrospective Cohort Study
38. 549 - Factors That Predict Early Relapse Post Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
39. 547 - Incidence of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
40. 548 - Analysis of Factors That Predict Progression Free and Overall Survival Post Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
41. 257 - The Characteristics of Multiple Myeloma Patients Referred for CAR T-Cell Therapy
42. Prospective review of SPEP orders confirms need for testing algorithm.
43. Clinical Utility of Chromosomal Microarray in Establishing Clonality and High Risk Features in Patients with Richter Transformation
44. Title: SNP Microarray Reveals Predicted Outcomes of a Novel High Risk AML Subgroup with ERG Amplification
45. Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers.
46. 53. Clinical utility of molecular profiling in the management of Richter syndrome
47. Menschen mit Behinderungen als Expertinnen und Experten bei Evaluationen?
48. An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma
49. Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis
50. Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.